Kadcyla 160 mg (Trastuzumab Emtansine) Powder for solution

Kadcyla 160 mg is a powder for solution used in targeted cancer therapy. This medication combines trastuzumab emtansine for intravenous administration, offering a precise approach to treatment.

Kadcyla 160 mg is primarily used in the treatment of certain types of breast cancer. It is designed for patients who have previously received other cancer treatments. This medication works by targeting specific cells, aiming to slow or stop the growth of cancer cells.

Common effects of Kadcyla 160 mg may include fatigue, nausea, and pain at the injection site. Some individuals might experience more severe side effects, and it is important to monitor any unusual symptoms closely.

Kadcyla 160 mg should be handled with care, following the instructions provided by healthcare professionals. It is crucial to store and administer this medication properly to ensure its effectiveness and safety. Always consult a healthcare provider before starting any new treatment.

Kadcyla 160 mg may interact with other medications, including those that affect the immune system. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions.